Looking for a Genomind Alternative? Here's What to Know

Pharmacogenetic Testing
Updated 2026-04-22 Medically reviewed content

You are looking for a Genomind alternative. Short answer: Gene2Rx covers the same core pharmacogenetic science (CPIC and FDA guidelines), does not require a provider order, works with 23andMe or AncestryDNA data you may already have, and costs $5 to $49 instead of several hundred dollars. Genomind's Genecept Assay includes some additional neuropsychiatric markers (SLC6A4, DRD2, MTHFR, COMT) with less established clinical actionability; Gene2Rx focuses on the genes where CPIC has published clinical guidelines and covers more medications outside psychiatry. See also our Gene2Rx vs GeneSight comparison if you're evaluating both psychiatric-focused tests.

When to Seek Immediate Help

Pharmacogenetic test results are not a diagnosis and should never be used to self-prescribe or change medications without medical guidance. Always discuss results with your healthcare provider before making any treatment changes.

Common Reasons This Can Happen

Genomind requires a clinician order and a new cheek swab

Like GeneSight, Genomind's Genecept Assay must be ordered by a healthcare provider and requires a new DNA sample (cheek swab). If you have already had your DNA tested through 23andMe, AncestryDNA, or a whole-genome sequencing service, you are essentially paying to re-sequence variants you already have on file. Gene2Rx analyzes pharmacogenetic variants directly from your existing data.

Cost and insurance coverage are unpredictable

Genomind's pricing depends on insurance coverage and can be hard to pin down upfront. Out-of-pocket costs for clinical PGx tests like Genomind and GeneSight often run from several hundred dollars to over a thousand. If you already own your genetic data, a service that analyzes existing files is significantly less expensive and has no insurance complexity.

Genomind focuses on psychiatry and neurology

Genomind's panel is built around psychiatric and neurological prescribing. It includes the core drug-metabolizing enzymes but also some genes beyond standard pharmacokinetics, such as the serotonin transporter (SLC6A4), dopamine receptor (DRD2), COMT, and MTHFR. The clinical actionability of these additional markers is actively debated; major clinical laboratory and genetics societies have not adopted them into formal dosing guidelines. For medications outside psychiatry (statins, blood thinners, pain medications, chemotherapy), Genomind's coverage is limited.

The core science is the same across reputable tests

All reputable pharmacogenetic tests, regardless of brand, analyze the same core drug-metabolizing enzyme genes (CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP3A5, CYP2B6, CYP1A2) using the same clinical guidelines from CPIC and the FDA. What differs between services is breadth of medication coverage, report format, cost, and whether a prescriber must be involved.

Could Your Genetics Be a Factor?

Whether you use Genomind, GeneSight, Gene2Rx, or another service, the pharmacogenetic genes with the strongest evidence are well-established. Here are the ones any good PGx test should cover.

CYP2D6

The most clinically important pharmacogene. Metabolizes many antidepressants (paroxetine, venlafaxine, fluoxetine, amitriptyline), ADHD medications (atomoxetine), pain medications (codeine, tramadol), tamoxifen, and beta-blockers (metoprolol). About 5 to 10 percent of people are poor metabolizers; 1 to 2 percent are ultrarapid metabolizers.

CYP2C19

Metabolizes SSRIs (sertraline, escitalopram, citalopram), clopidogrel (Plavix), proton pump inhibitors (omeprazole), and certain antifungals. Particularly important for cardiac patients on clopidogrel.

CYP2C9

Metabolizes warfarin and NSAIDs. Critical for patients on blood thinners, where dosing errors can cause bleeding or clotting.

SLCO1B1

Affects statin transport and statin-associated muscle pain risk. About 15 to 20 percent of people carry variants that increase susceptibility to statin side effects.

When comparing PGx services, focus on the genes that matter for your actual medications. If you are primarily managing psychiatric medications, CYP2D6 and CYP2C19 are most important. If you also take cardiovascular drugs, pain medications, or statins, coverage of CYP2C9, SLCO1B1, and VKORC1 matters. Genomind's additional neuropsychiatric markers may provide supplementary information, but CPIC-guideline genes are where the strongest evidence lies.

When to Consider Pharmacogenetic Testing

Pharmacogenetic testing is valuable any time you are starting a medication with strong PGx evidence, if you have struggled to find the right psychiatric medication, or if you want a comprehensive genetic profile to inform future prescribing. Your genetics do not change, so one test covers you for life.

What You Can Do Next

  1. Check whether you already have genetic data from 23andMe, AncestryDNA, or another testing service. If so, a new DNA sample may be unnecessary.
  2. Compare services on what matters to you: medication coverage, cost, whether a provider order is required, and report clarity.
  3. Consider Gene2Rx if you want a pharmacogenetic report covering 100+ medications across all drug classes, working with existing genetic data, and without requiring a doctor's order.
  4. Share your results with your prescribing provider. Pharmacogenetic information is most powerful when combined with clinical judgment.

Related Medications

Learn how genetics may affect your response to these related medications:

Related Guides

Frequently Asked Questions

How does Gene2Rx compare to Genomind?

Gene2Rx analyzes the pharmacogenetic variants in your existing 23andMe, AncestryDNA, or VCF data, covering 100+ medications across psychiatry, pain management, cardiology, and other drug classes. Genomind requires a provider order and a new cheek swab, focuses on psychiatric and neurological medications, and includes some neuropsychiatric markers (SLC6A4, DRD2, MTHFR) whose clinical actionability is debated. Gene2Rx is typically much more affordable because it uses existing data.

Does Genomind test genes that other services do not?

Genomind's panel includes markers like SLC6A4, DRD2, ADRA2A, and MTHFR that go beyond standard drug metabolism. The clinical actionability of these is less established than the core pharmacokinetic genes (CYP2D6, CYP2C19, etc.) that every reputable service covers. Guideline-backed PGx recommendations mostly come from the drug-metabolizing enzyme genes.

Is MTHFR testing useful for medication decisions?

MTHFR is included in some PGx panels, including Genomind's, because of its relationship to folate metabolism and potential mood effects. However, major clinical guidelines (including from CAP and ACMG) explicitly recommend against MTHFR genotyping for most clinical indications, because the research does not support using MTHFR variants to guide prescribing decisions. It is supplementary information rather than a primary driver of medication choices.

Can I use my Genomind results alongside Gene2Rx?

Yes. If you have already taken Genomind, those results are valid and useful. Gene2Rx can complement them by covering additional medications outside psychiatry (statins, blood thinners, pain medications) using your existing 23andMe or AncestryDNA data. The two reports together would give you the broadest pharmacogenetic picture without requiring a new Genomind test.

Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your medication. Never stop or change medication without medical supervision.
All Guides Sertraline Details

Already Have Genetic Data? Get a Comprehensive PGx Report Without a New Test.

Find out how your DNA may influence your response to Sertraline and other medications with a Gene2Rx pharmacogenetics report.

Get Your Report Try Our Free Calculator
Get Your Report Now
Ready in One Minute